Effect of adamantylamide dipeptide as adjuvant therapy to praziquantel in mice infected with different S. mansoni isolates.
This work investigated the possible use of AdDP as adjuvant therapy to praziquantel (PZQ) in mice infected with PZQ-insusceptible Schistosoma mansoni isolate in a trial to increase the susceptibility of this isolate to the drug. Two batches of C57 BL/6 mice were infected with PZQ-susceptible and -insusceptible S. mansoni isolates, and each batch was divided into five groups. Seven weeks postinfection, the experimental group received AdDP (5 mg/kg) in addition to PZQ in reduced dose (3x100 mg/kg). Three of the remaining four groups were treated controls; they received AdDP, PZQ in reduced dose and in full dose (2x500 mg/kg), and the fourth group was infected untreated. In mice infected with PZQ-susceptible or -insusceptible S. mansoni isolate, praziquantel alone, and in addition to AdDP, reduced worm and egg loads and increased percentage dead eggs. Also, they improved the histopathological changes (reduction in granuloma diameter, percentage fibrotic area with increased percentage degenerated eggs). Inducible nitric oxide synthase (iNOS), nitric oxide (NO) in culture of peritoneal macrophages, and number of CD68-positive cells were decreased with improved alanine amino transaminase. In mice receiving combined therapy AdDP+PZQ, the antischistosomal efficacy and the reductions in the inflammatory granulomatous reactions, NO in cultured peritoneal macrophages, percentage fibrotic areas recorded, were comparable to that in mice receiving full dose of PZQ, with significantly higher reduction in CD68 cells denoting enhanced antischistosomal efficacy and healing of the inflammatory reactions in the liver.
Botros
Sanaa
S
Department of Pharmacology, Theodor Bilharz Research Institute, Warrak El-Hadar, Imbaba, Giza, Egypt. sanaabotros@link.net
Mahmoud
Madiha
M
Hammam
Olfat
O
Salah
Faten
F
Zidek
Zdenek
Z
Masek
Karel
K
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000284:Administration, Oral; D000547:Amantadine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage*; D002478:Cells, Cultured; D004151:Dipeptides / Q000008:administration & dosage*; D005355:Fibrosis; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011223:Praziquantel / Q000008:administration & dosage*; D012550:Schistosoma mansoni / Q000187:drug effects / Q000276:immunology / Q000302:isolation & purification; D012555:Schistosomiasis mansoni / Q000188:drug therapy* / Q000469:parasitology / Q000473:pathology
D000276:Adjuvants, Immunologic; D000871:Anthelmintics; D004151:Dipeptides; D011223:Praziquantel; C044891:adamantylamide-alanyl-isoglutamine; D000547:Amantadine